S. Houston

发表

Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer

Mike J. Irwin, James D. Brenton, Carlos Caldas, 2016, Breast Cancer Research.

Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG.

S. Barrington, I. Fogelman, S. Houston, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.

C. Caldas, E. Provenzano, J. Abraham, 2015, The Lancet. Oncology.

Abstract S4-5: Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer. The AZURE Trial (BIG 01/04)

D. Cameron, D. Dodwell, C. Davies, 2010 .

Breast-cancer adjuvant therapy with zoledronic acid.

W. Gregory, D. Cameron, D. Dodwell, 2011, The New England journal of medicine.

Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions.

R. Rubens, I. Fogelman, M. Maisey, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer

D. Cameron, D. Dodwell, R. Bell, 2011, Breast Cancer Research and Treatment.

Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial.

R. Lerski, P. Ell, J. Mckillop, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The systemic treatment of bone metastases.

R. Rubens, S. Houston, 1995, Clinical orthopaedics and related research.

A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer.

R. Rubens, R. Coleman, S. Houston, 1998, European journal of cancer.

Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease.

R. Rubens, R. Coleman, R. Leonard, 1992, British Journal of Cancer.

Use of BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor (TKI), to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab.

E. Winer, T. Hickish, N. Lin, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TEXAS (Taxotere® EXperience with Anthracyclines Study) trial: mature results of activity/toxicity of docetaxel given with anthracyclines in a community setting, as first line therapy for MBC

A. Howell, S. Johnston, A. Wardley, 2006, Cancer Chemotherapy and Pharmacology.

A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases.

R. Rubens, J. Chatal, I. Fogelman, 1997, European journal of cancer.

Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.

H. Gundacker, M. Dowsett, D. Miles, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

P. Dziewulski, M. Gore, M. Highley, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer.

J. Hardy, J. Mansi, G. van Tienhoven, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923.

M. J. van de Vijver, D. Larsimont, M. Piccart, 2000, Clinical breast cancer.

Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.

J. Klijn, M. Piccart, R. Paridaens, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial.

R. Laing, C. Caldas, E. Provenzano, 2014, The Lancet. Oncology.

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.

M. Gore, P. Nathan, P. Lorigan, 2014, The Lancet. Oncology.

Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer

D. Miles, D. Barnes, R. Rubens, 1999, British Journal of Cancer.

Use of BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor To Treat Patients with HER2-Positive Metastatic Breast Cancer after Failure of Treatment with Trastuzumab.

L. Carey, T. Hickish, M. Uttenreuther-Fischer, 2009 .

The influence of adjuvant chemotherapy on outcome after relapse for patients with breast cancer.

R. Rubens, A. Bentley, P. Smith, 1993, European journal of cancer.

A dose-controlled study of Sm-153 -EDTMP in the treatment of patients with painful bone metastases

J. Chatal, I. Fogelman, A. Pecking, 1997 .

Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer.

M. Dowsett, P. Ellis, T. Hickish, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

Tamas Hickish, Pamela Munster, Eric P. Winer, 2012, Breast Cancer Research and Treatment.

Randomized trial of marker-directed versus standard schedule zoledronic acid for bone metastases from breast cancer.

L. Hayward, R. Coleman, P. Simmonds, 2012 .

Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer.

T. Powles, M. Dowsett, R. Coombes, 1996, British Journal of Cancer.

Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial

C. Caldas, E. Provenzano, J. Abraham, 2017, Modern Pathology.

Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study

F. Percival, T. Hickish, S. Houston, 2010, Journal of medical economics.

0-72. Rivizor® versus aminoglutethimide (AG) in the second-line endocrine treatment of postmenopausal patients with advanced breast cancer (ABC) following tamoxifen failure

S. Houston, 1997 .

Abstract PD2-3: ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy for patients with HER2-negative early breast cancer

C. Caldas, E. Provenzano, J. Abraham, 2015 .

Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Preplanned interim results for the AVAST-M trial.

M. Gore, P. Nathan, P. Lorigan, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination chemotherapy with epirubicin, cisplatin and 5‐fluorouracil for the palliation of advanced gastric and oesophageal adenocarcinoma

M. Highley, R. Penson, R. Mason, 1994, The British journal of surgery.

C. Caldas, E. Provenzano, J. Abraham, 2015, The Lancet. Oncology.